Nautilus Biotechnology (NAUT) Competitors $1.76 -0.04 (-2.22%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAUT vs. TRNS, CTKB, LAB, EYPT, AEHR, QTRX, SENS, QSI, FEIM, and KEQUShould you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and Kewaunee Scientific (KEQU). These companies are all part of the "measuring and control equipment" industry. Nautilus Biotechnology vs. Transcat Cytek Biosciences Standard BioTools EyePoint Pharmaceuticals Aehr Test Systems Quanterix Senseonics Quantum-Si Frequency Electronics Kewaunee Scientific Nautilus Biotechnology (NASDAQ:NAUT) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Is NAUT or TRNS more profitable? Transcat has a net margin of 6.63% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 7.36% beat Nautilus Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Nautilus BiotechnologyN/A -28.85% -24.93% Transcat 6.63%7.36%5.90% Does the media prefer NAUT or TRNS? In the previous week, Transcat had 10 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 10 mentions for Transcat and 0 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.00 beat Transcat's score of -0.39 indicating that Nautilus Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Nautilus Biotechnology Neutral Transcat Neutral Which has preferable earnings and valuation, NAUT or TRNS? Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNautilus BiotechnologyN/AN/A-$63.67M-$0.56-3.14Transcat$270.61M3.59$13.65M$1.9853.41 Do insiders & institutionals have more ownership in NAUT or TRNS? 50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 40.5% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 2.3% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, NAUT or TRNS? Nautilus Biotechnology has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Do analysts rate NAUT or TRNS? Nautilus Biotechnology presently has a consensus target price of $3.58, indicating a potential upside of 103.60%. Transcat has a consensus target price of $130.25, indicating a potential upside of 23.17%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nautilus Biotechnology 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Transcat 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community prefer NAUT or TRNS? Transcat received 206 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 66.88% of users gave Transcat an outperform vote while only 19.05% of users gave Nautilus Biotechnology an outperform vote. CompanyUnderperformOutperformNautilus BiotechnologyOutperform Votes419.05%Underperform Votes1780.95% TranscatOutperform Votes21066.88% Underperform Votes10433.12% SummaryTranscat beats Nautilus Biotechnology on 13 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAUT vs. The Competition Export to ExcelMetricNautilus BiotechnologyAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$220.99M$5.42B$5.12B$9.07BDividend YieldN/A0.43%4.91%4.22%P/E Ratio-3.1425.1891.3417.19Price / SalesN/A4.291,117.70116.80Price / CashN/A44.4542.6437.86Price / Book0.832.204.794.78Net Income-$63.67M$2.05M$120.07M$225.60M7 Day Performance-9.74%-2.70%-1.90%-1.23%1 Month Performance-26.05%-2.89%11.45%3.37%1 Year Performance-44.48%-28.70%30.63%16.58% Nautilus Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAUTNautilus Biotechnology1.625 of 5 stars$1.76-2.2%$3.58+103.6%-41.3%$220.99MN/A-3.14130High Trading VolumeTRNSTranscat2.7544 of 5 stars$109.27+0.1%$130.25+19.2%+2.4%$1.01B$270.61M54.911,104Analyst RevisionNews CoverageCTKBCytek Biosciences2.0636 of 5 stars$6.43+3.5%$9.25+43.9%-32.3%$828.26M$201.21M-77.63500Positive NewsLABStandard BioTools3.2471 of 5 stars$2.12+11.0%$2.88+35.6%+3.6%$789.19M$155.90M-2.99620News CoveragePositive NewsGap DownEYPTEyePoint Pharmaceuticals1.9425 of 5 stars$7.54+1.1%$25.71+241.0%-63.3%$514.61M$45.71M-3.79120News CoverageGap DownAEHRAehr Test Systems2.6061 of 5 stars$14.40+24.9%$25.00+73.6%-47.8%$426.69M$58.71M13.0090News CoverageGap UpHigh Trading VolumeQTRXQuanterix2.0118 of 5 stars$10.99+2.9%$23.25+111.6%-60.9%$421.80M$122.37M-10.09460SENSSenseonics2.5018 of 5 stars$0.46+1.8%$2.00+339.6%-27.3%$270.88M$22.39M-3.4490Analyst ForecastGap DownHigh Trading VolumeQSIQuantum-Si1.9199 of 5 stars$1.54-10.8%$3.25+111.7%-25.3%$219.06M$2.27M-2.36150High Trading VolumeFEIMFrequency Electronics2.233 of 5 stars$18.45+10.4%N/A+92.5%$176.51M$60.19M22.07200Analyst UpgradeNews CoverageHigh Trading VolumeKEQUKewaunee Scientific2.258 of 5 stars$54.80+2.6%N/A+107.4%$157.39M$199.64M8.461,006Analyst UpgradeInsider TradeGap Down Related Companies and Tools Related Companies TRNS Competitors CTKB Competitors LAB Competitors EYPT Competitors AEHR Competitors QTRX Competitors SENS Competitors QSI Competitors FEIM Competitors KEQU Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAUT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
